Verrica Pharmaceuticals Inc (VRCA) - Total Assets
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) holds total assets worth $36.02 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Verrica Pharmaceuticals Inc - Total Assets Trend (2016–2025)
This chart illustrates how Verrica Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Verrica Pharmaceuticals Inc (VRCA) market capitalisation for the company's overall valuation and market capitalisation.
Verrica Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Verrica Pharmaceuticals Inc's total assets of $36.02 Million consist of 90.3% current assets and 9.7% non-current assets. Review debt load of Verrica Pharmaceuticals Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 64.0% |
| Accounts Receivable | $5.40 Million | 11.5% |
| Inventory | $2.24 Million | 4.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Verrica Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Verrica Pharmaceuticals Inc (VRCA) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verrica Pharmaceuticals Inc's current assets represent 90.3% of total assets in 2025, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 64.0% of total assets in 2025, down from 96.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 11.5% of total assets.
Verrica Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Verrica Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Verrica Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.45 | 1.26 | 1.79 |
| Quick Ratio | 1.33 | 1.17 | 1.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $10.20 Million | $7.56 Million | $36.78 Million |
Verrica Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Verrica Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.42 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | -12.9% |
| Total Assets | $47.13 Million |
| Market Capitalization | $79.88 Million USD |
Valuation Analysis
Above Book Valuation: The market values Verrica Pharmaceuticals Inc's assets above their book value (1.69x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Verrica Pharmaceuticals Inc's assets decreased by 12.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Verrica Pharmaceuticals Inc (2016–2025)
The table below shows the annual total assets of Verrica Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $47.13 Million | -12.94% |
| 2024-12-31 | $54.13 Million | -33.66% |
| 2023-12-31 | $81.60 Million | +82.46% |
| 2022-12-31 | $44.72 Million | -44.19% |
| 2021-12-31 | $80.12 Million | +8.05% |
| 2020-12-31 | $74.15 Million | +8.37% |
| 2019-12-31 | $68.42 Million | -25.55% |
| 2018-12-31 | $91.91 Million | +911.85% |
| 2017-12-31 | $9.08 Million | +1569.67% |
| 2016-12-31 | $544.00K | -- |
About Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the tr… Read more